Innoviva (INVA) Stock Price, News & Analysis

Company Overview

Innoviva, Inc., incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches.

Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.

Key Stats

• Today's Range: $22.41 to $22.93
• 50-Day Range: $21.35 to $24.24
• 52-Week Range: $16.52 to $25.15
• Volume: 845,393 shs
• Average Volume: 870,504 shs
• Market Capitalization: $1.66 billion
• P/E Ratio: 3.75
• Dividend Yield: N/A
• Price Target: $36.20
• Consensus Rating: Moderate Buy

Innoviva Stock Analysis - MarketRank™

Innoviva scored higher than 63% of companies evaluated by MarketBeat, and ranked 301st out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Innoviva has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Innoviva has a consensus price target of $36.20, representing about 60.7% upside from its current price of $22.52.

Amount of Analyst Coverage

Innoviva has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.97%

Earnings Growth

Earnings for Innoviva are expected to grow by 8.97% in the coming year, from $2.23 to $2.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Innoviva is 3.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of Innoviva is 3.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.82.

Price to Book Value per Share Ratio

Innoviva has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.84% of the float of Innoviva has been sold short.

Short Interest Ratio / Days to Cover

Innoviva has a short interest ratio ("days to cover") of 9.55.

Change versus previous month

Short interest in Innoviva has recently increased by 1.81%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innoviva does not currently pay a dividend.

Dividend Growth

Innoviva does not have a long track record of dividend growth.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.10

News Sentiment

Innoviva has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Innoviva this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Innoviva to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innoviva insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.01% of the stock of Innoviva is held by insiders.

Percentage Held by Institutions

99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 6/06/2026
• Goldman Sachs 47th Annual Global Healthcare Conference 2026: 6/08/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INVA
• Previous Symbol: NASDAQ:THRX
• CIK: 1080014
• Web: www.inva.com
• Phone: (650) 238-9600
• Fax: 650-827-8690
• Employees: 100
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Innoviva: $36.20
• High Price Target: $46.00
• Low Price Target: $17.00
• Potential Upside/Downside: +60.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.01
• Trailing P/E Ratio: 3.75
• Forward P/E Ratio: 10.10
• P/E Growth: N/A
• Net Income: $271.17 million
• Net Margins: 119.89%
• Pretax Margin: 142.63%
• Return on Equity: 33.33%
• Return on Assets: 22.67%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 21.13
• Quick Ratio: 20.07

Sales & Book Value

• Annual Sales: $411.33 million
• Price / Sales: 4.04
• Cash Flow: $5.12 per share
• Price / Cash Flow: 4.40
• Book Value: $15.71 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 73,810,000
• Free Float: 72,325,000
• Market Cap: $1.66 billion
• Optionable: Optionable
• Beta: 0.35